公开(公告)号：US09527803B2

公开(公告)日：2016-12-27

申请号：US14006468

申请日：2012-03-22

申请人： Yu Huang ,  Ling Tong ,  Xueyan Zhu ,  Hanbin Shan ,  Zhedong Yuan ,  Xiong Yu

发明人： Yu Huang ,  Ling Tong ,  Xueyan Zhu ,  Hanbin Shan ,  Zhedong Yuan ,  Xiong Yu

IPC分类号： C07C231/24 ,  C07C233/22 ,  A61K9/48

CPC分类号： C07C233/22 ,  A61K9/4866 ,  C07C231/24 ,  C07C233/18

摘要： The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation.

摘要翻译： 本发明提供了一种新的结晶形式的阿莫西坦结晶形式VII，其制备方法，应用和药物组合物。 这种新的结晶形式提供高纯度，稳定的晶体结构和良好的再现性，而其生产方法适合大规模生产。 在稳定性和纯度方面，它优于迄今报道的许多结晶形式。 结果，本发明的结晶形式VII在药物制剂中具有优势。

公开(公告)号：US20140011883A1

公开(公告)日：2014-01-09

申请号：US14006468

申请日：2012-03-22

申请人： Yu Huang ,  Ling Tong ,  Xueyan Zhu ,  Hanbin Shan ,  Zhedong Yuan ,  Xiong Yu

发明人： Yu Huang ,  Ling Tong ,  Xueyan Zhu ,  Hanbin Shan ,  Zhedong Yuan ,  Xiong Yu

IPC分类号： C07C233/22 ,  C07C231/24

CPC分类号： C07C233/22 ,  A61K9/4866 ,  C07C231/24 ,  C07C233/18

摘要： The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation.

摘要翻译： 本发明提供了一种新的结晶形式的阿莫西坦结晶形式VII，其制备方法，应用和药物组合物。 这种新的结晶形式提供高纯度，稳定的晶体结构和良好的再现性，而其生产方法适合大规模生产。 在稳定性和纯度方面，它优于迄今报道的许多结晶形式。 结果，本发明的结晶形式VII在药物制剂中具有优点。

公开(公告)号：US08772488B2

公开(公告)日：2014-07-08

申请号：US13262093

申请日：2010-03-31

申请人： Zhedong Yuan ,  Xingdong Cheng ,  Yulei Yang ,  Ling Tong ,  Xiong Yu ,  Laifang Zhang ,  Wenliang Zhou

发明人： Zhedong Yuan ,  Xingdong Cheng ,  Yulei Yang ,  Ling Tong ,  Xiong Yu ,  Laifang Zhang ,  Wenliang Zhou

IPC分类号： A61K31/44 ,  C07D471/02 ,  A61K31/4365 ,  C07D495/04

CPC分类号： A61K31/4365 ,  C07D495/04

摘要： The present application discloses crystals of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.

摘要翻译： 本申请公开了2-乙酰氧基-5-（α-环丙基羰基-2-氟苄基）-4,5,6,7-四氢噻吩并[3,2-c]吡啶氢溴酸盐的晶体，晶体组合物和包含它们的药物组合物及其 使用。 本申请的普拉格罗氢溴酸盐晶体具有优异的稳定性和溶解性。

公开(公告)号：US20120095035A1

公开(公告)日：2012-04-19

申请号：US13262093

申请日：2010-03-31

申请人： Zhedong Yuan ,  Xingdong Cheng ,  Yulei Yang ,  Ling Tong ,  Xiong Yu ,  Laifang Zhang ,  Wenliang Zhou

发明人： Zhedong Yuan ,  Xingdong Cheng ,  Yulei Yang ,  Ling Tong ,  Xiong Yu ,  Laifang Zhang ,  Wenliang Zhou

IPC分类号： A61K31/4365 ,  A61P7/02 ,  C07D495/04

CPC分类号： A61K31/4365 ,  C07D495/04

摘要： The present application discloses crystals of 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrobromate, crystal compositions and pharmaceutical compositions comprising them and their use. The crystals of prasugrel hydrobromate of the present application possess excellent stability and solubility.

摘要翻译： 本申请公开了2-乙酰氧基-5-（α-环丙基羰基-2-氟苄基）-4,5,6,7-四氢噻吩并[3,2-c]吡啶氢溴酸盐的晶体，晶体组合物和包含它们的药物组合物及其 使用。 本申请的普拉格罗氢溴酸盐晶体具有优异的稳定性和溶解性。

公开(公告)号：US11921152B2

公开(公告)日：2024-03-05

申请号：US17531737

申请日：2021-11-20

申请人： Ling Tong

发明人： Ling Tong

IPC分类号： G01R31/28 ,  G01R23/16

CPC分类号： G01R31/2822

摘要： The method is for identifying a signal and its image signal input to the heterodyne frequency sweep system. Comparing to a traditional heterodyne frequency sweep technology, a mixing module with a positive and negative sign filters (PNS filters) is introduced, and the detection and identification module is added, and the typical low-pass filter in the input module is removed. According to the timing order sequence of the signal output from the intermediate frequency (IF) filter and PNS filters, a signal and its image signal can be identified. The bandwidth of the heterodyne frequency sweep system is not limited by the cut-off frequency of the low-pass filter (LPF) of the traditional heterodyne frequency sweep system.

公开(公告)号：US09433621B2

公开(公告)日：2016-09-06

申请号：US13579399

申请日：2011-02-18

申请人： Ashok Arasappan ,  F. George Njoroge ,  Cecil D. Kwong ,  Subramaniam Ananthan ,  Frank Bennett ,  Francisco Velazquez ,  Vinay M. Girijavallabhan ,  Yuhua Huang ,  Hollis S. Kezar, III ,  Joseph A. Maddry ,  Robert C. Reynolds ,  Abhijit Roychowdhury ,  Anita T. Fowler ,  John A. Secrist, III ,  Joseph A. Kozlowski ,  Bandarpalle B. Shankar ,  Ling Tong ,  Seong Heon Kim ,  Malcolm MacCoss ,  Srikanth Venkatraman ,  Vishal Verma

发明人： Ashok Arasappan ,  F. George Njoroge ,  Cecil D. Kwong ,  Subramaniam Ananthan ,  Frank Bennett ,  Francisco Velazquez ,  Vinay M. Girijavallabhan ,  Yuhua Huang ,  Hollis S. Kezar, III ,  Joseph A. Maddry ,  Robert C. Reynolds ,  Abhijit Roychowdhury ,  Anita T. Fowler ,  John A. Secrist, III ,  Joseph A. Kozlowski ,  Bandarpalle B. Shankar ,  Ling Tong ,  Seong Heon Kim ,  Malcolm MacCoss ,  Srikanth Venkatraman ,  Vishal Verma

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K48/00 ,  A01N37/18 ,  A61K38/00 ,  A61P1/16 ,  A61K51/00 ,  A61M36/14 ,  A61K31/506 ,  A61K45/06 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  C07D491/048 ,  C07D513/04 ,  C07D417/14

CPC分类号： A61K31/506 ,  A61K45/06 ,  C07D403/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D491/048 ,  C07D513/04

摘要： The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

公开(公告)号：US20140378416A1

公开(公告)日：2014-12-25

申请号：US14345114

申请日：2012-09-11

申请人： Michael P. Dwyer ,  Kartik M. Keertikar ,  Qingbei Zeng ,  Robert D. Mazzola, JR. ,  Wensheng Yu ,  Haiqun Tang ,  Seong Heon Kim ,  Ling Tong ,  Stuart B. Rosenblum ,  Joseph A. Kozlowski ,  Anilkumar Gopinadhan Nair

发明人： Michael P. Dwyer ,  Kartik M. Keertikar ,  Qingbei Zeng ,  Robert D. Mazzola, JR. ,  Wensheng Yu ,  Haiqun Tang ,  Seong Heon Kim ,  Ling Tong ,  Stuart B. Rosenblum ,  Joseph A. Kozlowski ,  Anilkumar Gopinadhan Nair

IPC分类号： C07F7/10 ,  A61K45/06 ,  A61K31/695

CPC分类号： C07F7/10 ,  A61K31/695 ,  A61K45/06 ,  A61K2201/094 ,  A61K2300/00 ,  C07F7/0816

摘要： The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

摘要翻译： 本发明涉及式（I）的新的含甲硅烷基的杂环化合物及其药学上可接受的盐，其中A，B，C，D，E，F和L如本文所定义。 本发明还涉及包含至少一种含甲硅烷基的杂环化合物的组合物，以及使用含有甲硅烷基的杂环化合物治疗或预防患者HCV感染的方法。

公开(公告)号：US08569336B2

公开(公告)日：2013-10-29

申请号：US13127953

申请日：2009-11-09

申请人： Ling Tong ,  Brian J. Lavey ,  Bandarpalle B. Shankar ,  Seong Heon Kim ,  Wensheng Yu ,  Joseph A. Kozlowski ,  Michael K. C. Wong ,  Lei Chen ,  Guowei Zhou ,  Razia K. Rizvi ,  Robert Feltz ,  Aneta Maria Kosinski ,  De-Yi Yang ,  Chaoyang Dai ,  Luke Fire ,  Vinay Girijavallabhan ,  Dansu Li ,  Janeta Popovici-Muller ,  Judson E. Richard ,  Kristin E. Rosner ,  M. Arshad Siddiqui ,  Liping Yang

发明人： Ling Tong ,  Brian J. Lavey ,  Bandarpalle B. Shankar ,  Seong Heon Kim ,  Wensheng Yu ,  Joseph A. Kozlowski ,  Michael K. C. Wong ,  Lei Chen ,  Guowei Zhou ,  Razia K. Rizvi ,  Robert Feltz ,  Aneta Maria Kosinski ,  De-Yi Yang ,  Chaoyang Dai ,  Luke Fire ,  Vinay Girijavallabhan ,  Dansu Li ,  Janeta Popovici-Muller ,  Judson E. Richard ,  Kristin E. Rosner ,  M. Arshad Siddiqui ,  Liping Yang

IPC分类号： A61K31/4166 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506 ,  C07D233/76 ,  C07D213/24

CPC分类号： C07D498/04 ,  C07D513/00 ,  C07D519/00

摘要： This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.

摘要翻译： 本发明涉及式（I）的化合物：（化学式应该插在这里，它以纸的形式出现）（I）或其药学上可接受的盐，其可用于治疗疾病或病症介导 通过MMP，ADAM，TACE，聚蛋白聚糖蛋白聚糖酶，TNF-或其组合。

公开(公告)号：US07253189B2

公开(公告)日：2007-08-07

申请号：US10721015

申请日：2003-11-21

申请人： Ling Tong ,  Lei Chen ,  Bandarpalle B. Shankar ,  Joseph A. Kozlowski ,  Neng-Yang Shih

发明人： Ling Tong ,  Lei Chen ,  Bandarpalle B. Shankar ,  Joseph A. Kozlowski ,  Neng-Yang Shih

IPC分类号： C07D401/02 ,  A61K31/44

CPC分类号： C07D401/12 ,  C07C317/32 ,  C07C323/31 ,  C07C323/41 ,  C07C323/49 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2602/08 ,  C07D213/71

摘要： A compound of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, L1, L2, M1, M2, n, p, q, A, D, X, Y and Z are as described in the specification; pharmaceutical compositions thereof, methods of making said pharmaceutical compositions; and methods of use thereof.

摘要翻译： 下式的化合物或其药学上可接受的盐或溶剂化物，其中：R 1，R 2，L 1，L 2， 2，M 1，M 2，n，p，q，A，D，X，Y和Z如说明书中所述; 药物组合物，制备所述药物组合物的方法; 及其使用方法。

公开(公告)号：US07067539B2

公开(公告)日：2006-06-27

申请号：US10214897

申请日：2002-08-07

申请人： Joseph A. Kozlowski ,  Neng-Yang Shih ,  Brian J. Lavey ,  Razia K. Rizvi ,  Bandarpalle B. Shankar ,  James M. Spitler ,  Ling Tong ,  Ronald L. Wolin ,  Michael K. Wong

发明人： Joseph A. Kozlowski ,  Neng-Yang Shih ,  Brian J. Lavey ,  Razia K. Rizvi ,  Bandarpalle B. Shankar ,  James M. Spitler ,  Ling Tong ,  Ronald L. Wolin ,  Michael K. Wong

IPC分类号： A61K31/444 ,  A61K31/435 ,  C07D213/70 ,  C07D213/71 ,  C07D213/89

CPC分类号： C07D213/70 ,  C07C31/24 ,  C07C317/22 ,  C07C317/32 ,  C07C317/36 ,  C07C317/44 ,  C07C323/41 ,  C07C323/65 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D213/71 ,  C07D213/74 ,  C07D213/89 ,  C07D215/36 ,  C07D233/42 ,  C07D233/84 ,  C07D239/38 ,  C07D307/64 ,  C07D333/20 ,  C07D333/34 ,  C07D333/38

摘要： The invention relates to compounds of the formula a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; which exhibit anti-inflammatory and immunodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds and methods of using the compounds for the treatment of various diseases and conditions.